Executive Director, Asset Team Lead (Biotech)

Location: Remote, based in the United States, with required periodic travel

Company

hirify.global is a clinical-stage TechBio company using AI, biology, chemistry, automation, and data science to industrialize drug discovery and develop medicines for significant unmet medical needs.

What you will do

• Define and drive asset strategy for small-molecule clinical programs in oncology and immunology/inflammation.
• Integrate competitive positioning, mechanistic differentiation, biomarker strategy, and patient segmentation into portfolio decisions.
• Translate hirify.global OS, ClinTech, proprietary data, and computational insights into strategic asset advantages.
• Develop and pressure-test competitive narratives for clinical assets to support leadership decisions, partnerships, and investor communications.
• Partner with clinical development, business development, finance, discovery, and platform leaders on resource allocation and portfolio priorities.

Requirements

• PhD in life sciences or a related scientific discipline.
• 10+ years of biotech or pharmaceutical experience with asset-level strategic leadership and clinical stage-gate advancement.
• Deep expertise in small-molecule therapeutics for oncology and immunology/inflammation.
• Experience using computational approaches and data-driven platforms for asset strategy and clinical decision-making.
• Strong financial acumen and ability to assess asset valuation, resourcing, and portfolio trade-offs.
• Exceptional executive presence with the ability to synthesize complex information into clear recommendations.

Nice to have

• Expertise in rare disease.

Culture & Benefits

• Cross-functional, analytically rigorous environment combining science and AI.
• Opportunity to work across clinical development, discovery, ClinTech, platform, and business development teams.
• Annual bonus eligibility and equity compensation.
• Comprehensive employee benefits package.
• Values-driven culture focused on integrity, ownership, rapid learning, collaboration, and patient impact.